Lentiviral-mediated BCL2 gene knockdown using comparative microRNA adaptive shRNAs

Area of Science:

• Molecular Biology
• Gene Therapy
• Cancer Research

Background:

• B-cell lymphoma 2 (BCL2) family proteins regulate cell death.
• BCL2 gene dysregulation is implicated in approximately half of human cancers.
• Targeting BCL2 offers a novel approach for cancer gene therapy.

Purpose of the Study:

• To optimize lentiviral-mediated RNA interference (RNAi) for BCL2 gene downregulation.
• To establish stable human embryonic kidney 293T (HEK293T) cell lines with suppressed BCL2 expression.
• To evaluate the efficiency of recombinant lentiviruses carrying anti-BCL2 short hairpin RNAs (shRNAs).

Main Methods:

• Utilized Dharmacon™ GIPZ™ shRNAmir lentiviral vectors targeting BCL2.
• Employed calcium phosphate precipitation for lentivirus packaging.
• Transduced HEK293T cells with lentiviruses and selected using puromycin.
• Assessed mRNA and protein levels via real-time PCR and Western blotting.

Main Results:

• Achieved high lentivirus packaging efficiency (>90% transfection rate).
• Successfully transduced HEK293T cells with recombinant lentiviruses.
• Demonstrated significant BCL2 gene downregulation (~90-95%) at the mRNA level in all treated groups compared to controls (p<0.01).
• Observed no significant differences in BCL2 downregulation among the different shRNA-treated groups (P > 0.05).

Conclusions:

• Lentivirus-mediated RNAi is an efficient technique for establishing cell lines with stable BCL2 gene downregulation.
• This method holds potential for developing novel cancer gene therapies targeting BCL2.